Respiratory Infections

Jacinda Abdul-Mutakabbir, PharmD, comments on building trust with community members and educating people about respiratory infection vaccines.

Experts share their approach to encouraging patients with symptoms of respiratory infections to get tested and vaccinated, and how that helps to control the spread of sickness.

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, and Jacinda Abdul-Mutakabbir, PharmD, discuss what both the clinician and the patient need to know about testing for respiratory viruses.

Priya Nori, MD, comments on the use of at-home tests for respiratory disease, including for COVID-19 and influenza.

The candidate, Ad26.RSV.preF–RSV preF protein vaccine, was 80.0% effective against severe disease and 69.8% effective against any RSV acute respiratory infection.

Why have “long COVID” cases become less frequent and less severe over time?

Jacinda Abdul-Mutakabbir, PharmD, examines the mechanisms of action of the different respiratory viral infection tests.

Experts review testing recommendations for respiratory viral infections and the types of testing options available.

Spherical hydrogel inhalation for enhanced lung defense (SHIELD) is an investigational inhalable that coats the airways and serves as a physical barrier against COVID-19.

Infectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.

Expert panelists continue the discussion of treatment for patients with coinfection of respiratory diseases.

Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, comment on the overlap of respiratory infections and their approach to getting people treatment.

New research suggests the majority of people hospitalized with influenza also had a chronic illness.

Can a similar approach that brought breakthrough therapies for cystic fibrosis bring about much needed change to antibiotic development?

The vast majority of COVID-19 infections are diagnosed at home, with rapid antigen tests. How has this affected public reports of COVID-19 prevalence?

University of Missouri investigators found people experiencing post-acute sequelae of COVID-19 (long COVID) are susceptible to developing 7 health defects in the year following infection.

The designation was based on positive top line data from the ConquerRSV phase 3 efficacy trial.

COVID-19 mortalities tend to be lowest in children, but the virus is still the #8 cause of death in children and young people 0-19 years old.

Experts provide an overview of the clinical presentations of respiratory infections such as COVID-19, influenza, and respiratory syncytial virus.

Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, discuss patient populations that are at greater risk of contracting and suffering from complications related to respiratory viruses.

The week's most-clicked COVID-19 stories included vaccine updates, new variants, and a pivotal FDA advisory committee vote.

What factors contribute to post-COVID-19 conditions (“long COVID”)? Can vaccination before or after a COVID-19 infection decrease the risk of long COVID?

Reported reasons adults had not received a bivalent COVID-19 booster dose differed across age groups.

Click on the slideshow images to read the full stories featured in this weekly infectious disease recap.

With these results, the company plans to submit their investigational vaccine, MRNA-1345, for regulatory approval in the first half of 2023.